I expect a 3x increase from the 40cent CR in speculation leading up to the Phase 3 trial during March 2025 (6 months away) waiting for April and with P3 readout success, a potential 6x to 16x increase by August 2026 on successful commercialization (US$5B company?). And of course, real but significantly smaller possibility of a 0x full loss of capital outcome.
Opthea Q&A Sep 2024 Update, page-32
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
82.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.000B | |||
| Open | High | Low | Value | Volume |
| 81.5¢ | 83.0¢ | 79.5¢ | $415.0K | 512.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2760 | 82.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.5¢ | 4435 | 8 |
View Market Depth
| Last trade - 14.13pm 12/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |